

# **Short acting bronchodilators for the inpatient management of COPD.**

*Study quality assessment & data extraction form*

**Reviewers Name:**

**Date of form completion:**

**RevMan Study ID**

## **References to this Trial**

Check other references identified in searches. If there are further references to this trial (i.e. multiple publications for the same study) link the papers now & list below. All references to a trial should be linked under one *Study ID* in RevMan.

Code each paper	References
	Format: [Surname] [initial], (etc). [Year of publication] [Title of paper]. [ <i>Journal title</i> ]; [volume] [(issue)]: [page numbers]

## **Methods:**

	Further details
Country:	
Design: (e.g., RCT)	
Objective: (Aim of the study)	
Study Site: (Hospital, specialist sleep clinic, research institute etc.)	
Methods of analysis: (e.g., Logistic regression etc.)	
Adjustment for clustering	

## **Participants:**

<i>(If multiple intervention/control arms label as 1. 2. 3. etc.)</i>	Further details	
	<u>Intervention:</u>	<u>Control:</u>
Eligible for study (n-value):		
Randomised: (n-value for each arm of study randomised)		
Completed: (participant completion n-value for each		

arm of study)		
Age: (mean value &/or range for each arm)		
Gender: (for each arm)		
COPD diagnosis criteria		
Recruitment: (through what means, e.g., outpatient clinics etc.)		
Diseases/co-morbidities included:		
Reasons for Subject Exclusion:		

***Interventions:***

	Further details
Setting:	
Duration of intervention: (weeks and hours)	
Intervention description	
Control description	

***Outcomes:***

	Further details
List the pre specified outcomes:	
Notes:	

**Data extraction**

<b><u>Outcomes relevant to your review</u></b>	<b><u>Continuous=C Dichotomous=D</u></b>	<b><u>Reported in paper (YES / NO)</u></b>
Avoidance of treatment failure i.e. avoided ICU		
Dyspnoea		
Sputum purulence/production		
FEV1		
FVC		
Quality of Life		
FOSQ		
SF36		
Nottingham health profile (part 2)		
Euroqol		
General Health Questionnaire (GHQ-28)		
SAQLI		
Other		
Adverse Events		
Readmission rate		
ED presentations		
Length of stay		
Hospital admissions		



### ***Risk of Bias Assessment***

Domain	Judgement	
<p><b>Adequate sequence generation</b> Was the allocation sequence adequately generated?</p>		
<p><b>Allocation Concealment</b> Was allocation adequately concealed?</p>		
<p><b>Blinding</b> Was knowledge of the allocated interventions adequately prevented during the study?</p>		
<p><b>For participants</b> Describe the methods used to blind participants awareness of group assignment</p>		
<p><b>For assessors</b> Describe the methods used to blind outcome assessor(s) of group assignment for each outcome</p>		
<p><b>Incomplete outcome data addressed</b> Were incomplete outcome data adequately addressed?</p>		
<p><b>Free of selective reporting</b> Are reports of the study free of suggestion of selective outcome reporting?</p>		
<p><b>Free of other bias</b> Was the study apparently free of other problems that could put it at a high risk of bias?</p>		

For Continuous data at day 0								
Outcomes	Unit of measurement	5mg group			10 mg group			Details of outcome as described in text
		n	Mean	SD	n	Mean	SD	

**For Continuous data at day 0**

Outcomes	Unit of measurement	5mg group			10 mg group			Details of outcome as described in text
		n	Mean	SD	n	Mean	SD	

For Dichotomous data							
Outcome	Intervention Group			Control Group			Details of outcome as described in text
	Number with event (n)	Total number (n)	%	Number with event (n)	Total number (n)	%	

**If more than one intervention please complete separate page for each intervention group**

**If continuous data is not presented as SD, type the format at the top of the SD column (i.e. SE, CI, p, diff)**



(Adapted from: Wynne R, Botti M & Paratz J)

Comprehensive list of tools used to measure each of the above outcomes				
Outcome	Name of tool	Scale/range	Direction	Validated
<b>Other comments</b>				

(Adapted from: Wynne R, Botti M & Paratz J)

**Extra notes:**

-